Insights On Upstream Manufacturing

31. NGS In GMP Manufacturing: Reducing Risk, Increasing Return 1/29/2026

    Global regulators now recognize NGS as a rigorous, GMP‑ready tool for viral safety, driving a shift toward scalable quality strategies. Learn why NGS is becoming central to modern manufacturing.

32. Enabling NGS-Based Product Characterization And Biosafety Assays 1/29/2026

    Evolving regulations are shaping the adoption of NGS for biosafety and product characterization. Learn what teams must consider when validating modern sequencing assays within GMP‑regulated environments.

33. Advanced NGS Techniques For Cell Line Characterization In CGT 1/29/2026

    Discover how in‑house NGS and robust data management streamline CQA analysis, reduce risk, and strengthen development workflows from early research through manufacturing.

34. Genetic Stability Testing Using NGS And MAM 1/29/2026

    New sequencing and analytical strategies offer deeper insight and greater confidence in long-term cell line performance. Explore how modern tools improve accuracy while simplifying development workflows.

35. Next-Gen Cell Line Characterization For Safer, Faster Drug Development 1/29/2026

    Modern development depends on thoroughly characterized cell lines. See how next‑generation sequencing strengthens identity, purity, and stability assessments while supporting global regulatory standards.

36. Simplified Harvest And Media Exchange In Cell Therapy 1/28/2026

    Scale-up often introduces shear stress and process variability. Learn how low-shear, single-use technology stabilizes media exchange and harvest, ensuring consistent cell quality and predictable performance.

37. From Fed-Batch To Continuous: How Perfusion Enables Smarter Biologics Production 1/28/2026

    Growing biologics demand is driving interest in perfusion culture as a complementary manufacturing strategy that enables continuous nutrient control, higher productivity, and performance when paired with fed-batch processes.

38. Manufacturing of "MSC 2.0" Using Functionally Closed Systems 1/27/2026

    Transitioning to closed systems enables the 100-fold expansion of engineered cells. Achieve high yields and maintain anti-cancer potency while reducing contamination risks and labor.

39. Why You Should Not Rely On Western Blotting For HCP Antibody Coverage 1/27/2026

    Legacy methods often mask critical impurities. Discover why traditional blotting may be jeopardizing your regulatory data and how to implement more sensitive, objective alternatives.

40. Choosing The Right Sample For HCP Antibody Coverage Analysis 1/27/2026

    Selecting the right sample is vital for accurate HCP antibody coverage. Learn how to navigate the limitations of traditional methods and ensure your ELISA is truly fit-for-purpose.